Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EAU 2022 | The case against including genomics in defining high-risk prostate cancer

Steven Joniau, MD, PhD, University Hospitals Leuven, Leuven, The Netherlands, gives an overview of why genomic testing should not be incorporated in staging prostate cancer. Access to genetic testing is scant, with only BRCA gene testing available. Current staging of prostate cancer is typically carried out with clinical parameters such as PET CT scans and incorporating genomic markers may result in redefining treatment regimens and clinical practice. This interview took place at the European Association of Urology (EAU) Meeting 2022.


Prof. Joniau reports the following conflicts of interest:
Research funding:  Astrellas, Bayer, Ferring, Janssen, MDX Health, Roche
Speakers fee: Astrellas, AstraZeneca, Bayer, Ferring, GSK, Ipsen, Janssen, Pfizer, Sanofi
Consultation fee: Astrellas, Bayer, Ipsen, Janssen, Roche